Golden Biotechnology Corporation (TPEX:4132)

Market Cap	3.90B
Revenue (ttm)	44.58M
Net Income (ttm)	-314.93M
Shares Out	162.23M
EPS (ttm)	-1.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,177,192
Average Volume	1,868,419
Open	21.60
Previous Close	21.60
Day's Range	21.45 - 24.45
52-Week Range	9.98 - 36.30
Beta	0.67
RSI	58.96
Earnings Date	Apr 27, 2026

About Golden Biotechnology

Golden Biotechnology Corporation operates as a drug discovery and healthy food supplement manufacturing company in Taiwan, the United States, Japan, China, Korea, and Singapore. Its products include Liverty that is used for liver health support and fatigue; Rasle, an auto-immune adjuvant therapy; ZSAINO, a nourishment product for recovery from illness and for health improvement; and UMOOZE, a herbal formula for optimal health in males. The company also provides Antroquinonol, an anticancer molecule for the treatment of pancreatic cancer, acute ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 122
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4132

Financial Performance

In 2024, Golden Biotechnology's revenue was 40.92 million, a decrease of -35.49% compared to the previous year's 63.43 million. Losses were -360.70 million, -0.26% less than in 2023.